
Yannick Allanore

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5338503/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. Clinical Reviews in Allergy and Immunology, 2023, 64, 239-261.	6.5	20
2	Representativeness of systemic sclerosis patients in interventional randomized trials: an analysis of the EUSTAR database. Rheumatology, 2022, 61, 743-755.	1.9	5
3	Quality of life in SSc-ILD patients: Understanding the impact of the ILD and the needs of the SSc-ILD patients and their need for caregivers in France. Journal of Scleroderma and Related Disorders, 2022, 7, 49-56.	1.7	5
4	The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19. Rheumatology, 2022, 61, 1600-1609.	1.9	53
5	Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score. Arthritis and Rheumatology, 2022, 74, 518-526.	5.6	21
6	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. Journal of Scleroderma and Related Disorders, 2022, 7, 24-32.	1.7	25
7	Revue des récents essais randomisés dans la sclérodermie systémique. Revue Du Rhumatisme (Edition)	Tj ETQq1	1 0.784314
8	Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire. Annals of the Rheumatic Diseases, 2022, 81, 507-515.	0.9	10
9	Improvement with time of vascular outcomes in systemic sclerosis: a systematic review and meta-analysis study. Rheumatology, 2022, 61, 2755-2769.	1.9	17
10	Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis. Arthritis Research and Therapy, 2022, 24, 19.	3.5	8
11	Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models. Arthritis Research and Therapy, 2022, 24, 13.	3.5	6
12	The role of antifibrotic therapies in the treatment of systemic sclerosis–associated interstitial lung disease. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2110666.	2.7	0
13	Erosive arthritis autoantibodies in systemic sclerosis. Seminars in Arthritis and Rheumatism, 2022, 52, 151947.	3.4	7
14	Dyspnoea and cough in patients with systemic sclerosis–associated interstitial lung disease in the SENSCIS trial. Rheumatology, 2022, 61, 4397-4408.	1.9	11
15	Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement/progression?. Rheumatology, 2022, 61, 4384-4396.	1.9	10
16	Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment. Rheumatology, 2022, 61, 4035-4046.	1.9	6
17	Driving Role of Interleukinâ€2–Related Regulatory <scp>CD4</scp> + T Cell Deficiency in the Development of Lung Fibrosis and Vascular Remodeling in a Mouse Model of Systemic Sclerosis. Arthritis and Rheumatology, 2022, 74, 1387-1398.	5.6	13
18	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. Rheumatology, 2022, 61, 4786-4796.	1.9	20

#	Article	IF	CITATIONS
19	Données récentes sur la prise en charge clinique de la sclérodermie systémique. Revue Du Rhumatisme (Edition Francaise), 2021, 88, 24-31.	0.0	0
20	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. Journal of Scleroderma and Related Disorders, 2021, 6, 66-76.	1.7	12
21	Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Annals of the Rheumatic Diseases, 2021, 80, 219-227.	0.9	160
22	Genomic Risk Score impact on susceptibility to systemic sclerosis. Annals of the Rheumatic Diseases, 2021, 80, 118-127.	0.9	20
23	Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis. Expert Review of Clinical Immunology, 2021, 17, 85-100.	3.0	14
24	Successful treatment of severe interstitial pneumonia by removal of circulating autoantibodies: a case series. BMC Pulmonary Medicine, 2021, 21, 13.	2.0	3
25	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respiratory Medicine,the, 2021, 9, 96-106.	10.7	118
26	The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. Rheumatology, 2021, 60, 5028-5041.	1.9	34
27	Natural variability in the disease course of SSc-ILD: implications for treatment. European Respiratory Review, 2021, 30, 200340.	7.1	18
28	Ethnic influence on the phenotype of French patients with systemic sclerosis. Joint Bone Spine, 2021, 88, 105081.	1.6	13
29	Rapidly Progressive Systemic Sclerosis–associated Interstitial Lung Disease After Intravesical Bacillus Calmette-Guérin Therapy for Early-stage Bladder Cancer. Journal of Rheumatology, 2021, 48, 1348-1349.	2.0	2
30	Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes. Annals of the Rheumatic Diseases, 2021, 80, 1040-1047.	0.9	24
31	Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials. Arthritis Research and Therapy, 2021, 23, 119.	3.5	13
32	A Practical Approach to the Management of Digital Ulcers in Patients With Systemic Sclerosis. JAMA Dermatology, 2021, 157, 851-858.	4.1	12
33	French recommendations for the management of systemic sclerosis. Orphanet Journal of Rare Diseases, 2021, 16, 322.	2.7	37
34	Semaphorins: From Angiogenesis to Inflammation in Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 1579-1588.	5.6	15
35	An update on recent randomized clinical trials in systemic sclerosis. Joint Bone Spine, 2021, 88, 105184.	1.6	2
36	Influence de l'origine ethnique sur le phénotype de patients atteints de sclérodermie systémique en France. Revue Du Rhumatisme (Edition Francaise), 2021, 89, 176-176.	0.0	0

#	Article	IF	CITATIONS
37	Successful treatment with baricitinib of refractory arthritis in a patient with severe diffuse cutaneous systemic sclerosis-rheumatoid arthritis overlap syndrome. Clinical and Experimental Rheumatology, 2021, 39 Suppl 131, 163-164.	0.8	0
38	Worldwide Expert Agreement on Updated Recommendations for the Treatment of Systemic Sclerosis. Journal of Rheumatology, 2020, 47, 249-254.	2.0	23
39	Patient perception of disease burden in diffuse cutaneous systemic sclerosis. Journal of Scleroderma and Related Disorders, 2020, 5, 66-76.	1.7	7
40	Systemic sclerosis: Recent insight in clinical management. Joint Bone Spine, 2020, 87, 293-299.	1.6	31
41	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase <scp>II</scp> Investigatorâ€initiated, Multicenter, Doubleâ€Blind, Randomized, Placeboâ€Controlled Trial. Arthritis and Rheumatology, 2020, 72, 125-136.	5.6	163
42	Estrogens Counteract the Profibrotic Effects of TGF-β and their Inhibition Exacerbates Experimental Dermal Fibrosis. Journal of Investigative Dermatology, 2020, 140, 593-601.e7.	0.7	15
43	Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. Rheumatology, 2020, 59, 1684-1694.	1.9	27
44	Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. Rheumatology, 2020, 59, 2016-2023.	1.9	14
45	Stem cells: Hope for systemic sclerosis patients?. Joint Bone Spine, 2020, 87, 285-288.	1.6	2
46	Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database. Autoimmunity Reviews, 2020, 19, 102452.	5.8	43
47	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. Lancet Rheumatology, The, 2020, 2, e743-e753.	3.9	34
48	Systemic sclerosis pathogenesis: contribution of recent advances in genetics. Current Opinion in Rheumatology, 2020, 32, 505-514.	4.3	30
49	Úlceras digitales en esclerosis sistémica. Revista Colombiana De ReumatologÃa, 2020, 27, 26-35.	0.1	0
50	The need for a holistic approach for SSc-ILD – achievements and ambiguity in a devastating disease. Respiratory Research, 2020, 21, 197.	3.6	33
51	The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients. Expert Review of Clinical Immunology, 2020, 16, 1065-1074.	3.0	5
52	Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database. Arthritis Research and Therapy, 2020, 22, 257.	3.5	20
53	A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Annals of the Rheumatic Diseases, 2020, 79, 1600-1607.	0.9	69
54	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2020, 8, 963-974.	10.7	348

#	Article	IF	CITATIONS
55	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. Annals of the Rheumatic Diseases, 2020, 79, 724-726.	0.9	51
56	Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease. PLoS ONE, 2020, 15, e0232978.	2.5	26
57	Implication of the deacetylase sirtuin-1 on synovial angiogenesis and persistence of experimental arthritis. Annals of the Rheumatic Diseases, 2020, 79, 891-900.	0.9	13
58	Digital ulcers in systemic sclerosis. Revista Colombiana De ReumatologÃa (English Edition), 2020, 27, 26-35.	0.0	0
59	Treatment of systemic sclerosis–associated interstitial lung disease: Lessons from clinical trials. Journal of Scleroderma and Related Disorders, 2020, 5, 61-71.	1.7	43
60	Randomised controlled trials in systemic sclerosis: patient selection and endpoints for next generation trials. Lancet Rheumatology, The, 2020, 2, e173-e184.	3.9	12
61	Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis. Arthritis and Rheumatology, 2020, 72, 1049-1058.	5.6	27
62	Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience. Seminars in Arthritis and Rheumatism, 2020, 50, 1489-1493.	3.4	33
63	Raynaud phenomenon and digital ulcers in systemic sclerosis. Nature Reviews Rheumatology, 2020, 16, 208-221.	8.0	115
64	Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosis. Arthritis Research and Therapy, 2020, 22, 30.	3.5	20
65	Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand?. Seminars in Arthritis and Rheumatism, 2020, 50, 480-491.	3.4	41
66	Ochronosis of the spine mimicking ankylosing spondylitis successfully treated with anakinra. Joint Bone Spine, 2020, 87, 368-369.	1.6	3
67	Pseudotumoral calcinosis in systemic sclerosis: Data from systematic literature review and case series from two referral centres. Seminars in Arthritis and Rheumatism, 2020, 50, 1339-1347.	3.4	12
68	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Annals of the Rheumatic Diseases, 2020, 79, 618-625.	0.9	71
69	Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice. Seminars in Arthritis and Rheumatism, 2020, 50, 1449-1456.	3.4	29
70	Treatment of systemic sclerosis associated ILD: Lessons from clinical trials. Journal of Scleroderma and Related Disorders, 2020, 5, 61-71.	1.7	14
71	Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. Annals of the Rheumatic Diseases, 2019, 78, 1576-1582.	0.9	31
72	IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosis. European Respiratory Journal, 2019, 54, 1900154.	6.7	31

#	Article	IF	CITATIONS
73	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. Nature Communications, 2019, 10, 4955.	12.8	100
74	Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. Annals of the Rheumatic Diseases, 2019, 78, 1242-1248.	0.9	39
75	Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. Arthritis Research and Therapy. 2019. 21. 130.	3.5	19
76	Reply. Arthritis and Rheumatology, 2019, 71, 1204-1206.	5.6	0
77	Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features. RMD Open, 2019, 5, e000826.	3.8	35
78	Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Annals of the Rheumatic Diseases, 2019, 78, 648-656.	0.9	79
79	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1553-1570.	5.6	75
80	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Annals of the Rheumatic Diseases, 2019, 78, 979-987.	0.9	142
81	Systemic sclerosis: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000782.	3.8	91
82	FRI0303â€THE EFFECTS OF RIOCIGUAT ON RAYNAUD'S PHENOMENON AND DIGITAL ULCERS IN PATIENTS DIFFUSE SYSTEMIC SCLEROSIS: RESULTS FROM THE PHASE IIB RISE-SSC STUDY. , 2019, , .	WITH	0
83	FRI0325â€IDENTIFYING SYSTEMIC SCLEROSIS PATIENTS AT RISK OF PROGRESSIVE LUNG FIBROSIS – A EUST DATABASE ANALYSIS. , 2019, , .	AR	0
84	OP0239â€PROGRESSIVE LUNG FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE IN THE EUSTAR DATABASE. , 2019, , .		1
85	SAT0273â€PREDICTIVE VALUE OF THE REVISED EUROPEAN SCLERODERMA TRIALS AND RESEARCH GROUP ACTIVITY INDEX (EUSTAR-AI). , 2019, , .		0
86	OP0227â€EFFECTS OF SUCCESSIVE SWITCHES TO DIFFERENT BIOSIMILARS INFLIXIMAB ON IMMUNOGENICIT CHRONIC INFLAMMATORY DISEASES IN DAILY CLINICAL PRACTICE. , 2019, , .	Y IN	1
87	SAT0254â€VASODILATOR THERAPY IN THE LONG TERM PREVENTION OF MYOCARDIAL MANIFESTATIONS IN SYSTEMIC SCLEROSIS (SSC): RESULTS FROM DESSCIPHER INCEPTION COHORT STUDY. , 2019, , .		0
88	OP0183â€EFFICACY AND SAFETY OF RIOCIGUAT IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS AND INTERSTITIAL LUNG DISEASE (SSC-ILD): RESULTS FROM THE PHASE IIB RISE-SSC STUDY. , 2019, , .		2
89	OP0065â€THE VERY EARLY DIAGNOSIS OF SYSTEMIC SCLEROSIS (VEDOSS) PROJECT: PREDICTORS TO DEVEL DEFINITE DISEASE FROM AN INTERNATIONAL MULTICENTRE STUDY. , 2019, , .	OP	1
90	Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual. Annals of the Rheumatic Diseases, 2019, 78, 1681-1685.	0.9	13

#	Article	IF	CITATIONS
91	Trained immunity modulates inflammation-induced fibrosis. Nature Communications, 2019, 10, 5670.	12.8	80
92	Impact of EUSTAR standardized training on accuracy of modified Rodnan skin score in patients with systemic sclerosis. International Journal of Rheumatic Diseases, 2019, 22, 96-102.	1.9	6
93	Hemodynamic changes after acute fluid loading in patients with systemic sclerosis without pulmonary hypertension. Pulmonary Circulation, 2019, 9, 1-6.	1.7	11
94	Comparison of the clinical phenotype of systemic sclerosis patients in Iran and France in two university centers. Journal of Scleroderma and Related Disorders, 2019, 4, 149-159.	1.7	5
95	Performance of Candidate Serum Biomarkers for Systemic Sclerosis–Associated Interstitial Lung Disease. Arthritis and Rheumatology, 2019, 71, 972-982.	5.6	101
96	18F-fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis. Annals of the Rheumatic Diseases, 2019, 78, 577-578.	0.9	17
97	Systemic sclerosis and primary biliary cholangitis: An overlapping entity?. Journal of Scleroderma and Related Disorders, 2019, 4, 111-117.	1.7	6
98	Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus. Seminars in Arthritis and Rheumatism, 2019, 48, 686-693.	3.4	34
99	Digital Ulcers, Vasculopathy and Internal Organ Involvement. , 2019, , 79-85.		0
100	Common measure of quality of life for people with systemic sclerosis across seven European countries: a cross-sectional study. Annals of the Rheumatic Diseases, 2018, 77, 1032-1038.	0.9	14
101	Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study. Seminars in Arthritis and Rheumatism, 2018, 48, 149-154.	3.4	55
102	Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry. Respiration, 2018, 95, 244-250.	2.6	17
103	Avancées thérapeutiques dans l'atteinte interstitielle pulmonaire au cours de la sclérodermie systémique. Revue Du Rhumatisme Monographies, 2018, 85, 165-170.	0.0	1
104	Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group. Rheumatology, 2018, 57, 441-450.	1.9	60
105	Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France. Seminars in Arthritis and Rheumatism, 2018, 47, 741-748.	3.4	63
106	Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Annals of the Rheumatic Diseases, 2018, 77, 212-220.	0.9	236
107	Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis. Arthritis and Rheumatology, 2018, 70, 162-170.	5.6	48
108	Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. RMD Open, 2018, 4, e000757.	3.8	28

#	Article	IF	CITATIONS
109	Targeting Costimulatory Pathways in Systemic Sclerosis. Frontiers in Immunology, 2018, 9, 2998.	4.8	30
110	Regulatory T Cells in Systemic Sclerosis. Frontiers in Immunology, 2018, 9, 2356.	4.8	67
111	<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. New England Journal of Medicine, 2018, 379, 2209-2219.	27.0	326
112	T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis. Arthritis Research and Therapy, 2018, 20, 197.	3.5	40
113	European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis. Rheumatology, 2018, 58, 254-259.	1.9	11
114	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. Arthritis and Rheumatology, 2018, 70, 1829-1834.	5.6	15
115	Soluble CD163 as a Potential Biomarker in Systemic Sclerosis. Disease Markers, 2018, 2018, 1-5.	1.3	25
116	Interstitial pneumonia with autoimmune features: a new classification still on the move. European Respiratory Review, 2018, 27, 180047.	7.1	15
117	Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Research and Therapy, 2018, 20, 17.	3.5	75
118	Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis. Arthritis and Rheumatology, 2018, 70, 1634-1643.	5.6	74
119	Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. Annals of the Rheumatic Diseases, 2018, 77, 1326-1332.	0.9	100
120	From VEDOSS to established systemic sclerosis diagnosis according to ACR/EULAR 2013 classification criteria: a French-Italian capillaroscopic survey. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 82-87.	0.8	5
121	Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 68-75.	0.8	3
122	Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening. Journal of Rheumatology, 2017, 44, 639-647.	2.0	93
123	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Annals of the Rheumatic Diseases, 2017, 76, 270-276.	0.9	132
124	Sequential nailfold videocapillaroscopy examinations have responsiveness to detect organ progression in systemic sclerosis. Seminars in Arthritis and Rheumatism, 2017, 47, 86-94.	3.4	71
125	Takayasu Arteritis and Spondyloarthritis: Coincidence or Association? A Study of 14 Cases. Journal of Rheumatology, 2017, 44, 1011-1017.	2.0	15
126	Use of biologics and other novel therapies for the treatment of systemic sclerosis. Expert Review of Clinical Immunology, 2017, 13, 469-482.	3.0	29

#	Article	IF	CITATIONS
127	Cardiovascular magnetic resonance in systemic sclerosis: "Pearls and pitfalls― Seminars in Arthritis and Rheumatism, 2017, 47, 79-85.	3.4	42
128	Transethnic meta-analysis identifies <i>CSDMA</i> and <i>PRDM1</i> as susceptibility genes to systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1150-1158.	0.9	77
129	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American Journal of Human Genetics, 2017, 100, 64-74.	6.2	78
130	Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1327-1339.	0.9	794
131	Points to consider when doing a trial primarily involving the heart. Rheumatology, 2017, 56, v12-v16.	1.9	6
132	Muscle involvement in systemic sclerosis: points to consider in clinical trials. Rheumatology, 2017, 56, v38-v44.	1.9	27
133	Points to consider for skin ulcers in systemic sclerosis. Rheumatology, 2017, 56, v67-v71.	1.9	59
134	Mapping and predicting mortality from systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1897-1905.	0.9	410
135	An international SUrvey on non-iNvaSive tecHniques to assess the mlcrocirculation in patients with RayNaud's phEnomenon (SUNSHINE survey). Rheumatology International, 2017, 37, 1879-1890.	3.0	33
136	The limited cutaneous form of systemic sclerosis is associated with urinary incontinence: an international multicentre study. Rheumatology, 2017, 56, 1874-1883.	1.9	10
137	Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis. Arthritis and Rheumatology, 2017, 69, 2209-2221.	5.6	17
138	Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. Annals of the Rheumatic Diseases, 2017, 76, 1931-1940.	0.9	67
139	Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. European Heart Journal, 2017, 38, 2649-2662.	2.2	163
140	Mortality profile of patients with rheumatoid arthritis in France and its change in 10 years. Seminars in Arthritis and Rheumatism, 2017, 46, 537-543.	3.4	25
141	Points to consider for designing trials in systemic sclerosis patients with arthritic involvement. Rheumatology, 2017, 56, v23-v26.	1.9	9
142	Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis. Journal of Scleroderma and Related Disorders, 2017, 2, 11-18.	1.7	321
143	The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study. Rheumatology, 2017, 56, 844-852.	1.9	13
144	What have multicentre registries across the world taught us about the disease features of systemic sclerosis?. Journal of Scleroderma and Related Disorders, 2017, 2, 169-182.	1.7	18

#	Article	IF	CITATIONS
145	Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) Definition. Journal of Scleroderma and Related Disorders, 2017, 2, 115-120.	1.7	62
146	Genetic Factors. , 2017, , 25-38.		0
147	Patient phenotypes in fibromyalgia comorbid with systemic sclerosis or rheumatoid arthritis: influence of diagnostic and screening tests. Screening with the FiRST questionnaire, diagnosis with the ACR 1990 and revised ACR 2010 criteria. Clinical and Experimental Rheumatology, 2017, 35 Suppl 105, 35-42.	0.8	12
148	Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 114-121.	0.8	1
149	Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Annals of the Rheumatic Diseases, 2016, 75, 103-109.	0.9	93
150	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Annals of the Rheumatic Diseases, 2016, 75, 163-169.	0.9	82
151	Systemic sclerosis trial design moving forward. Journal of Scleroderma and Related Disorders, 2016, 1, 177-180.	1.7	42
152	Effect of endothelin-1 receptor antagonists on skin fibrosis in scleroderma patients from the EUSTAR database. Journal of Scleroderma and Related Disorders, 2016, 1, 220-225.	1.7	3
153	Limited cutaneous systemic sclerosis: the unfairly neglected subset. Journal of Scleroderma and Related Disorders, 2016, 1, 241-246.	1.7	20
154	Late Nailfold Videocapillaroscopy Pattern Associated With Hand Calcinosis and Acroâ€Osteolysis in Systemic Sclerosis. Arthritis Care and Research, 2016, 68, 366-373.	3.4	40
155	Dr. Pène, <i>et al</i> reply. Journal of Rheumatology, 2016, 43, 677-677.	2.0	Ο
156	Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: a prospective, observational cohort. Annals of the Rheumatic Diseases, 2016, 75, 1736-1740.	0.9	34
157	Treatment of systemic sclerosis: is there any hope for the future?: TableÂ1. RMD Open, 2016, 2, e000260.	3.8	19
158	Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. Annals of the Rheumatic Diseases, 2016, 75, 2175-2183.	0.9	68
159	Small, medium but not large arteries are involved in digital ulcers associated with systemic sclerosis. Joint Bone Spine, 2016, 83, 444-447.	1.6	10
160	Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet, The, 2016, 387, 2630-2640.	13.7	505
161	N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis. International Journal of Cardiology, 2016, 223, 385-389.	1.7	16
162	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Care and Research, 2016, 68, 167-178.	3.4	13

#	Article	IF	CITATIONS
163	OX40L blockade protects against inflammation-driven fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3901-10.	7.1	50
164	Skin Telangiectasia and the Identification of a Subset of Systemic Sclerosis Patients With Severe Vascular Disease. Arthritis Care and Research, 2016, 68, 1021-1027.	3.4	28
165	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis and Rheumatology, 2016, 68, 299-311.	5.6	110
166	Digital ulcers predict a worse disease course in patients with systemic sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 681-686.	0.9	111
167	Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey. Seminars in Arthritis and Rheumatism, 2016, 46, 115-123.	3.4	84
168	Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Annals of the Rheumatic Diseases, 2016, 75, 1285-1292.	0.9	56
169	Decreased expression of neuropilin-1 as a novel key factor contributing to peripheral microvasculopathy and defective angiogenesis in systemic sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 1541-1549.	0.9	38
170	A right ventricular diastolic impairment is common in systemic sclerosis and is associated with other target-organ damage. Seminars in Arthritis and Rheumatism, 2016, 45, 439-445.	3.4	23
171	Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. PLoS ONE, 2016, 11, e0163894.	2.5	158
172	Early phase clinical and biological markers associated with subclinical atherosclerosis measured at 7 years of evolution in an early inflammatory arthritis cohort. Clinical and Experimental Rheumatology, 2016, 34, 58-67.	0.8	7
173	A candidate gene study identifies a haplotype of CD2 as novel susceptibility factor for systemic sclerosis. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 43-48.	0.8	1
174	Effects of rituximab in connective tissue disorders related interstitial lung disease. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 181-185.	0.8	20
175	Identification of NF-κB and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis. Arthritis Research and Therapy, 2015, 17, 71.	3.5	41
176	Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. Rheumatology, 2015, 54, 1262-1269.	1.9	25
177	Advances in cohort enrichment shape future of trial design. Nature Reviews Rheumatology, 2015, 11, 72-74.	8.0	19
178	Systemic sclerosis: Recent insights. Joint Bone Spine, 2015, 82, 148-153.	1.6	54
179	Identification of secreted phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility gene. Annals of the Rheumatic Diseases, 2015, 74, e19-e19.	0.9	24
180	Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. Rheumatology, 2015, 54, 144-151.	1.9	30

#	Article	IF	CITATIONS
181	A very rare cause of acro-osteolysis: Hajdu-Cheney syndrome. Joint Bone Spine, 2015, 82, 455-459.	1.6	7
182	Outcome of Patients with Systemic Sclerosis in the Intensive Care Unit. Journal of Rheumatology, 2015, 42, 1406-1412.	2.0	19
183	Targeting CD226/DNAX accessory molecule-1 (DNAM-1) in collagen-induced arthritis mouse models. Journal of Inflammation, 2015, 12, 9.	3.4	14
184	A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) gene and systemic sclerosis. Arthritis Research and Therapy, 2015, 17, 128.	3.5	24
185	Cardiac Biomarkers in Systemic Sclerosis: Contribution of Highâ€Sensitivity Cardiac Troponin in Addition to Nâ€Terminal Proâ€Brain Natriuretic Peptide. Arthritis Care and Research, 2015, 67, 1022-1030.	3.4	54
186	Systemic sclerosis. Nature Reviews Disease Primers, 2015, 1, 15002.	30.5	587
187	Une cause rare d'acro-ostéolyseÂ: le syndrome de Hadju-Cheney. Revue Du Rhumatisme (Edition) Tj ETQq1	1,0,7843 0.0	14 rgBT /O
188	All-cause Mortality Associated with TNF-α Inhibitors in Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials. American Journal of Medicine, 2015, 128, 1367-1373.e1.	1.5	8
189	Autoantibodies against Endothelin 1 Type A Receptor Are Strong Predictors of Digital Ulcers in Systemic Sclerosis. Journal of Rheumatology, 2015, 42, 1801-1807.	2.0	46
190	Trabecular Bone Score in Female Patients with Systemic Sclerosis: Comparison with Rheumatoid Arthritis and Influence of Glucocorticoid Exposure. Journal of Rheumatology, 2015, 42, 228-235.	2.0	42
191	Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Annals of the Rheumatic Diseases, 2015, 74, 1188-1194.	0.9	340
192	Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis. Clinical and Experimental Rheumatology, 2015, 33, S31-5.	0.8	4
193	Prevalence, Correlates and Outcomes of Gastric Antral Vascular Ectasia in Systemic Sclerosis: A EUSTAR Case-control Study. Journal of Rheumatology, 2014, 41, 99-105.	2.0	73
194	Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. Arthritis Research and Therapy, 2014, 16, R157.	3.5	68
195	The Nuclear Receptor Constitutive Androstane Receptor/NR1I3 Enhances the Profibrotic Effects of Transforming Growth Factor Î ² and Contributes to the Development of Experimental Dermal Fibrosis. Arthritis and Rheumatology, 2014, 66, 3140-3150.	5.6	13
196	Flare of calcinosis despite rituximab therapy. Seminars in Arthritis and Rheumatism, 2014, 44, e5-e6.	3.4	18
197	Anticyclic Citrullinated Peptide Antibodies in Rheumatoid and Nonrheumatoid Rheumatic Disorders: Experience with 1162 Patients. Journal of Rheumatology, 2014, 41, 2395-2402.	2.0	63
198	Cardiac arrhythmias and conduction defects in systemic sclerosis. Rheumatology, 2014, 53, 1172-1177.	1.9	83

#	Article	IF	CITATIONS
199	Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Annals of the Rheumatic Diseases, 2014, 73, 2087-2093.	0.9	168
200	Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis. Annals of the Rheumatic Diseases, 2014, 73, 191-197.	0.9	41
201	Systemic Sclerosis-related Acute Myocardial Infarction: Definition. American Journal of Medicine, 2014, 127, e37.	1.5	0
202	International consensus criteria for the diagnosis of Raynaud's phenomenon. Journal of Autoimmunity, 2014, 48-49, 60-65.	6.5	170
203	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. Journal of Clinical Epidemiology, 2014, 67, 706-714.	5.0	52
204	Association study of CRP gene in systemic sclerosis in European Caucasian population. Rheumatology International, 2014, 34, 389-392.	3.0	2
205	Correlations between angiogenic factors and capillaroscopic patterns in systemic sclerosis. Arthritis Research and Therapy, 2013, 15, R55.	3.5	62
206	Systemic sclerosis at the crossroad of polyautoimmunity. Autoimmunity Reviews, 2013, 12, 1052-1057.	5.8	62
207	Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Annals of the Rheumatic Diseases, 2013, 72, 1696-1699.	0.9	148
208	Combination of Echocardiographic and Pulmonary Function Test Measures Improves Sensitivity for Diagnosis of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: Analysis of 2 Cohorts. Journal of Rheumatology, 2013, 40, 1706-1711.	2.0	23
209	Incomplete thymic involution in systemic sclerosis and rheumatoid arthritis. Joint Bone Spine, 2013, 80, 48-51.	1.6	12
210	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatism, 2013, 65, 2737-2747.	6.7	2,359
211	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2013, 72, 1747-1755.	0.9	1,705
212	Comparison of Pain, Pain Burden, Coping Strategies, and Attitudes Between Patients with Systemic Sclerosis and Patients with Rheumatoid Arthritis: A Cross-Sectional Study. Pain Medicine, 2013, 14, 1776-1785.	1.9	37
213	Experimental models of dermal fibrosis and systemic sclerosis. Joint Bone Spine, 2013, 80, 23-28.	1.6	17
214	Performance of Skin Ultrasound to Measure Skin Involvement inÂDifferent Animal Models of Systemic Sclerosis. Ultrasound in Medicine and Biology, 2013, 39, 845-852.	1.5	5
215	Brief Report: A Regulatory Variant in <i>CCR6</i> Is Associated With Susceptibility to Antitopoisomeraseâ€Positive Systemic Sclerosis. Arthritis and Rheumatism, 2013, 65, 3202-3208.	6.7	26
216	Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis. Annals of the Rheumatic Diseases, 2013, 72, 1089-1098.	0.9	35

#	ARTICLE	IF	CITATIONS
217	Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Annals of the Rheumatic Diseases, 2013, 72, 1217-1220.	0.9	160
218	Decreased expression of the endothelial cell-derived factor EGFL7 in systemic sclerosis: potential contribution to impaired angiogenesis and vasculogenesis. Arthritis Research and Therapy, 2013, 15, R165.	3.5	18
219	Epistatic Interaction between BANK1 and BLK in Rheumatoid Arthritis: Results from a Large Trans-Ethnic Meta-Analysis. PLoS ONE, 2013, 8, e61044.	2.5	24
220	Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Annals of the Rheumatic Diseases, 2012, 71, 1355-1360.	0.9	275
221	Evidence for caveolin-1 as a new susceptibility gene regulating tissue fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases, 2012, 71, 1034-1041.	0.9	33
222	Angiogenic biomarkers predict the occurrence of digital ulcers in systemic sclerosis. Annals of the Rheumatic Diseases, 2012, 71, 394-399.	0.9	53
223	Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology, 2012, 51, 1017-1026.	1.9	345
224	Independent Replication and Metaanalysis of Association Studies Establish TNFSF4 as a Susceptibility Gene Preferentially Associated with the Subset of Anticentromere-positive Patients with Systemic Sclerosis. Journal of Rheumatology, 2012, 39, 997-1003.	2.0	35
225	Articular involvement in systemic sclerosis. Rheumatology, 2012, 51, 1347-1356.	1.9	76
226	Increased risk of osteoporosis and fracture in women with systemic sclerosis: A comparative study with rheumatoid arthritis. Arthritis Care and Research, 2012, 64, 1871-1878.	3.4	68
227	Familial Autoimmunity in Systemic Sclerosis — Results of a French-based Case-Control Family Study. Journal of Rheumatology, 2012, 39, 532-538.	2.0	24
228	Ultrasonographic hand features in systemic sclerosis and correlates with clinical, biologic, and radiographic findings. Arthritis Care and Research, 2012, 64, 1244-1249.	3.4	53
229	Inhibition of activator protein 1 signaling abrogates transforming growth factor β–mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis and Rheumatism, 2012, 64, 1642-1652.	6.7	81
230	Brief Report: Candidate gene study in systemic sclerosis identifies a rare and functional variant of the <i>TNFAIP3</i> locus as a risk factor for polyautoimmunity. Arthritis and Rheumatism, 2012, 64, 2746-2752.	6.7	63
231	Phosphodiesterase 5 inhibitors in vascular systemic disorders. Joint Bone Spine, 2012, 79, 338-340.	1.6	3
232	Spleen Calcifications in Connective Tissue Disorders. Seminars in Arthritis and Rheumatism, 2012, 41, e1-e2.	3.4	2
233	Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Research and Therapy, 2011, 13, R166.	3.5	148
234	Génétique et physiopathologie de la sclérodermie systémique. Bulletin De L'Academie Nationale De Medecine, 2011, 195, 55-67.	0.0	0

#	Article	IF	CITATIONS
235	A genetic variation located in the promoter region of the <i>UPAR</i> (<i>CD87</i>) gene is associated with the vascular complications of systemic sclerosis. Arthritis and Rheumatism, 2011, 63, 247-256.	6.7	41
236	Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis and Rheumatism, 2011, 63, 800-809.	6.7	73
237	C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: Results from a large french cohort and meta-analysis. Arthritis and Rheumatism, 2011, 63, 2091-2096.	6.7	45
238	Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. Arthritis and Rheumatism, 2011, 63, 2790-2796.	6.7	53
239	Insights into the pathogenesis of systemic sclerosis based on the gene expression profile of progenitorâ€derived endothelial cells. Arthritis and Rheumatism, 2011, 63, 3552-3562.	6.7	26
240	Enhanced expression of ephrins and thrombospondins in the dermis of patients with early diffuse systemic sclerosis: potential contribution to perturbed angiogenesis and fibrosis. Rheumatology, 2011, 50, 1494-1504.	1.9	21
241	Association Study of <i>ITGAM, ITGAX,</i> and <i>CD58</i> Autoimmune Risk Loci in Systemic Sclerosis: Results from 2 Large European Caucasian Cohorts. Journal of Rheumatology, 2011, 38, 1033-1038.	2.0	22
242	Genome-Wide Scan Identifies TNIP1, PSORS1C1, and RHOB as Novel Risk Loci for Systemic Sclerosis. PLoS Genetics, 2011, 7, e1002091.	3.5	205
243	A Diffuse Scleroderma Patient Who Presents with Shortness of Breath and Enlarged Cardiac Silhouette. , 2011, , 139-145.		0
244	The genetics of systemic sclerosis: an update. Clinical and Experimental Rheumatology, 2011, 29, S75-86.	0.8	40
245	Updating the genetics of systemic sclerosis. Current Opinion in Rheumatology, 2010, 22, 665-670.	4.3	16
246	Usefulness of routine electrocardiography for heart disease screening in patients with spondyloarthropathy or rheumatoid arthritis. Joint Bone Spine, 2010, 77, 146-150.	1.6	10
247	Association of a <i>KCNA5</i> gene polymorphism with systemic sclerosis–associated pulmonary arterial hypertension in the European Caucasian population. Arthritis and Rheumatism, 2010, 62, 3093-3100.	6.7	49
248	Description d'une nouvelle mutation de LRP5Âchez un patient atteint d'un syndrome ostéoporose–pseudogliome. Revue Du Rhumatisme (Edition Francaise), 2010, 77, 179-181.	0.0	1
249	Anti-RNA Polymerase III Antibody Prevalence and Associated Clinical Manifestations in a Large Series of French Patients with Systemic Sclerosis: A Cross-sectional Study. Journal of Rheumatology, 2010, 37, 125-130.	2.0	53
250	Prevalence of Pulmonary Hypertension in Systemic Sclerosis in European Caucasians and Metaanalysis of 5 Studies. Journal of Rheumatology, 2010, 37, 2290-2298.	2.0	259
251	Dermal tissue and cellular expression of fibrillin-1 in diffuse cutaneous systemic sclerosis. Rheumatology, 2010, 49, 657-661.	1.9	10
252	Characteristics of Joint Involvement and Relationships with Systemic Inflammation in Systemic Sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) Database. Journal of Rheumatology, 2010, 37, 1488-1501.	2.0	161

#	Article	IF	CITATIONS
253	Genetic background of systemic sclerosis: autoimmune genes take centre stage. Rheumatology, 2010, 49, 203-210.	1.9	42
254	Associated Autoimmune Diseases in Systemic Sclerosis Define a Subset of Patients with Milder Disease: Results from 2 Large Cohorts of European Caucasian Patients. Journal of Rheumatology, 2010, 37, 608-614.	2.0	73
255	Phenotype-Haplotype Correlation of <i>IRF5</i> in Systemic Sclerosis: Role of 2 Haplotypes in Disease Severity. Journal of Rheumatology, 2010, 37, 987-992.	2.0	54
256	Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Annals of the Rheumatic Diseases, 2010, 69, 1809-1815.	0.9	1,017
257	Heart involvement in systemic sclerosis: Evolving concept and diagnostic methodologies. Archives of Cardiovascular Diseases, 2010, 103, 46-52.	1.6	112
258	Association Study of Serotonin Transporter Gene (SLC6A4) in Systemic Sclerosis in European Caucasian Populations. Journal of Rheumatology, 2010, 37, 1164-1167.	2.0	10
259	Pulmonary arterial hypertension occurrence after liver transplant in systemic sclerosis: a report of 2 cases sustainably treated by sildenafil. Clinical and Experimental Rheumatology, 2010, 28, S53-4.	0.8	2
260	Lack of Specificity of the 6-Minute Walk Test as an Outcome Measure for Patients with Systemic Sclerosis. Journal of Rheumatology, 2009, 36, 1481-1485.	2.0	57
261	TNF receptor-associated periodic syndrome (TRAPS): A new cause of joint destruction?. Joint Bone Spine, 2009, 76, 567-569.	1.6	8
262	The threeâ€year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis and Rheumatism, 2009, 60, 1831-1839.	6.7	179
263	Le TNF Receptor-Associated Periodic Syndrome (TRAPS)Â: nouvelle cause d'atteinte articulaire érosiveÂ?. Revue Du Rhumatisme (Edition Francaise), 2009, 76, 918-921.	0.0	0
264	Angiotensin-Converting Enzyme Gene Does Not Contribute to Genetic Susceptibility to Systemic Sclerosis in European Caucasians. Journal of Rheumatology, 2009, 36, 337-340.	2.0	15
265	Vitamin D Deficiency and Insufficiency in 2 Independent Cohorts of Patients with Systemic Sclerosis. Journal of Rheumatology, 2009, 36, 1924-1929.	2.0	84
266	Association of hypoxiaâ€inducible factor 1A (<i>HIF1A</i>) gene polymorphisms with systemic sclerosis in a French European Caucasian population. Scandinavian Journal of Rheumatology, 2009, 38, 291-294.	1.1	29
267	Sclérodermie systémiqueÂ: état des lieux en 2008. Revue Du Rhumatisme (Edition Francaise), 2008, 75, 918-924.	0.0	0
268	High N-terminal pro–brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis and Rheumatism, 2008, 58, 284-291.	6.7	225
269	Cardiac involvement in systemic sclerosis assessed by tissueâ€doppler echocardiography during routine care: A controlled study of 100 consecutive patients. Arthritis and Rheumatism, 2008, 58, 1803-1809.	6.7	171
270	Endothelial progenitor cells and rheumatic disorders. Joint Bone Spine, 2008, 75, 131-137.	1.6	42

#	Article	IF	CITATIONS
271	Systemic sclerosis: an update in 2008. Joint Bone Spine, 2008, 75, 650-655.	1.6	54
272	Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opinion on Pharmacotherapy, 2008, 9, 1121-1128.	1.8	67
273	Is sitaxsentan a good therapeutic option for pulmonary arterial hypertension associated with connective tissue disease?. Nature Clinical Practice Rheumatology, 2008, 4, 238-239.	3.2	1
274	Usefulness of Multidetector Computed Tomography to Assess Calcinosis in Systemic Sclerosis. Journal of Rheumatology, 2008, 35, 2274-2275.	2.0	7
275	Systemic sclerosis and cardiac dysfunction: evolving concepts and diagnostic methodologies. Current Opinion in Rheumatology, 2008, 20, 697-702.	4.3	38
276	New therapeutic strategies in the management of systemic sclerosis. Expert Opinion on Pharmacotherapy, 2007, 8, 607-615.	1.8	49
277	Cardiovascular mortality in patients with inflammatory rheumatic disorders. Joint Bone Spine, 2007, 74, 120-122.	1.6	6
278	Cardiovascular disease in rheumatoid arthritis: Single-center hospital-based cohort study in France. Joint Bone Spine, 2007, 74, 66-72.	1.6	48
279	Genetic basis for systemic sclerosis. Joint Bone Spine, 2007, 74, 577-583.	1.6	56
280	Myocardial dysfunction in rheumatoid arthritis: a controlled tissue-Doppler echocardiography study. Journal of Rheumatology, 2007, 34, 2005-9.	2.0	14
281	Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clinica Chimica Acta, 2006, 365, 143-148.	1.1	69
282	Evaluation of interleukin 13 polymorphisms in systemic sclerosis. Immunogenetics, 2006, 58, 693-699.	2.4	42
283	Treatment ofÂsystemic sclerosis. Joint Bone Spine, 2006, 73, 363-368.	1.6	20
284	IL13RA2 gene polymorphisms are associated with systemic sclerosis. Journal of Rheumatology, 2006, 33, 2015-9.	2.0	40
285	Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study. Journal of Rheumatology, 2006, 33, 2464-9.	2.0	53
286	Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. Arthritis and Rheumatism, 2005, 52, 3792-3800.	6.7	656
287	Myocardial contractility is early affected in systemic sclerosis: A Tissue Doppler echocardiography study. European Journal of Echocardiography, 2005, 6, 351-357.	2.3	54
288	Nifedipine protects against overproduction of superoxide anion by monocytes from patients with systemic sclerosis. Arthritis Research, 2005, 7, R93.	2.0	28

#	Article	IF	CITATIONS
289	Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1. Arthritis Research, 2004, 6, R309.	2.0	43
290	Lack of association of eNOS (G894T) and p22phox NADPH oxidase subunit (C242T) polymorphisms with systemic sclerosis in a cohort of French Caucasian patients. Clinica Chimica Acta, 2004, 350, 51-55.	1.1	23
291	Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. American Journal of Medicine, 2004, 116, 595-600.	1.5	83
292	Multiple spontaneous visceral hematomas revealing polyarteritis nodosa. Journal of Rheumatology, 2004, 31, 1858-60.	2.0	3
293	High prevalence of right ventricular systolic dysfunction in early systemic sclerosis. Journal of Rheumatology, 2004, 31, 1941-5.	2.0	59
294	Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis. Journal of Rheumatology, 2003, 30, 68-73.	2.0	25
295	Systemic Sclerosis. European Medical Journal Rheumatology, 0, , 100-109.	0.0	4